Search

Your search keyword '"De Bari, B"' showing total 479 results
Start Over Author "De Bari, B"
479 results on '"De Bari, B"'

2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.

Published
2019
Full Text
View/download PDF

4. Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

Author

Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, and Franco P

Subjects
NLR, PLR, SII, Anal cancer, prognostic factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Andrea Casadei-Gardini,1 Francesco Montagnani,2 Chiara Casadei,1 Francesca Arcadipane,3 Kalliopi Andrikou,4 Deborah Aloi,5 Alessandra Anna Prete,6,7 Maria Giulia Zampino,8 Antonella Argentiero,9 Giuseppe Pugliese,4 Stefania Martini,10 Giuseppe Carlo Iorio,10 Mario Scartozzi,11 Massimiliano Mistrangelo,12 Lorenzo Fornaro,13 Paola Cassoni,14 Giorgia Marisi,15 Veronica Dell’Acqua,16 Paola Simona Ravenda,8 Sara Lonardi,6 Nicola Silvestris,7 Berardino De Bari,5 Umberto Ricardi,3 Stefano Cascinu,4 Pierfrancesco Franco91Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; 2Oncology Department, SOC Oncology, ASL (Health Local Authority), Biella, Italy; 3Department of Oncology, Radiation Oncology, AOU Città della Salute e della Scienza, Turin, Italy; 4Department of Hematology and Oncology, University of Modena and Reggio Emilia, Modena, Italy; 5Radiation Oncology Department, Centre Hospitalier Régional Universitaire “Jean Minjoz”, Besançon Cedex, France; 6Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy; 7Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I University Hospital, Rome, Italy; 8Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy; 9Medical Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy; 10Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy; 11Department of Medical Oncology, University of Cagliari, Cagliari, Italy; 12Department of Surgical Sciences, University of Turin, Turin, Italy; 13Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana University, Pisa, Italy; 14Department of Medical Sciences, Pathology Unit, University of Turin, Turin, Italy; 15Biosciences Laboratory, Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy; 16Department of Radiotherapy, IRCCS, European Institute of Oncology, Milan, ItalyBackground: In anal cancer, there are no markers nor other laboratory indexes that can predict prognosis and guide clinical practice for patients treated with concurrent chemoradiation. In this study, we retrospectively investigated the influence of immune inflammation indicators on treatment outcome of anal cancer patients undergoing concurrent chemoradiotherapy.Methods: All patients had a histologically proven diagnosis of squamous cell carcinoma of the anal canal/margin treated with chemoradiotherapy according to the Nigro’s regimen. Impact on prognosis of pre-treatment systemic index of inflammation (SII) (platelet x neutrophil/lymphocyte), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were analyzed.Results: A total of 161 consecutive patients were available for the analysis. Response to treatment was the single most important factor for progression-free survival (PFS) and overall survival (OS). At univariate analysis, higher SII level was significantly correlated to lower PFS (p

Published
2019

7. OC-0270 Metastases-directed SRT and systemic therapy: EORTC-ESTRO OligoCare delphi consensus recommendations

Author

Kroeze, S., primary, Pavic, M., additional, Stellamans, K., additional, Lievens, Y., additional, Becherini, C., additional, Scorsetti, M., additional, Alongi, F., additional, Ricardi, U., additional, Jereczek, B., additional, Westhoff, P., additional, But-Hadzic, J., additional, Widder, J., additional, Geets, X., additional, Bral, S., additional, Lambrecht, M., additional, Billiet, C., additional, Sirak, I., additional, Ramella, S., additional, Battista, I.G., additional, Benavente, S., additional, Zapatero, A., additional, Romero, F., additional, Zilli, T., additional, Khanfir, K., additional, Hemmatazad, H., additional, De Bari, B., additional, Klass, D., additional, Adnan, S., additional, Peulen, H., additional, Salinas Ramos, J., additional, Strijbos, M., additional, Popat, S., additional, Ost, P., additional, and Guckenberger, M., additional

Published
2023
Full Text
View/download PDF

9. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

Author

Salas, S., Resseguier, N., Blay, J.Y., Le Cesne, A., Italiano, A., Chevreau, C., Rosset, P., Isambert, N., Soulie, P., Cupissol, D., Delcambre, C., Bay, J.O., Dubray-Longeras, P., Krengli, M., De Bari, B., Villa, S., Kaanders, J.H.A.M., Torrente, S., Pasquier, D., Thariat, J.O., Myroslav, L., Sole, C.V., Dincbas, H.F., Habboush, J.Y., Zilli, T., Dragan, T., Khanfir, K., Ugurluer, G., Cena, T., Duffaud, F., Penel, N., Bertucci, F., Ranchere-Vince, D., Terrier, P., Bonvalot, S., Macagno, N., Lemoine, C., Lae, M., Coindre, J.M., and Bouvier, C.

Published
2017
Full Text
View/download PDF

13. OC-0602 A pREDictive model of polymetastatic disease on oligometastatic colorectal cancer: the RED LaIT-SABR

Author

Nicosia, L., primary, Franceschini, D., additional, Perrone Congedi, F., additional, Casamassima, F., additional, Gerardi, M.A., additional, Rigo, M., additional, Mazzola, R., additional, Perna, M., additional, Scotti, V., additional, Fodor, A., additional, Iurato, A., additional, Pasqualetti, F., additional, Gadducci, G., additional, Chiesa, S., additional, Niespolo, R.M., additional, Bruni, A., additional, Alicino, G., additional, Frassinelli, L., additional, Borghetti, P., additional, Di Marzo, A., additional, Ravasio, A., additional, De Bari, B., additional, Sepulcri, M., additional, Aiello, D., additional, Mortellaro, G., additional, Sangalli, C., additional, Franceschini, M., additional, Montesi, G., additional, Aquilanti, F.M., additional, Lunardi, G., additional, Valdagni, R., additional, Fazio, I., additional, Corti, L., additional, Vavassori, V., additional, Maranzano, E., additional, Magrini, S.M., additional, Arcangeli, S., additional, Valentini, V., additional, Paiar, F., additional, Ramella, S., additional, Di Muzio, N.G., additional, Livi, L., additional, Jereczek- Fossa, B.A., additional, Osti, M.F., additional, Scorsetti, M., additional, and Alongi, F., additional

Published
2022
Full Text
View/download PDF

16. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comperat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmuller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinos E, Logager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Muller AC, Muller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupret M, Rouviere O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van der Heijden AG, Van Poppel H, Vartolomei MD, Veskimae E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A, Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A., UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, Ja, Babjuk, M, Bellmunt, J, Bruins, Hm, De Reijke, Tm, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, Mj, Shariat, Sf, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, Pc, Bochner, Bh, Bolla, M, Boormans, Jl, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, Pjl, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, Jl, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, Jj, Gakis, G, Geavlete, B, Gontero, P, Grubmuller, B, Hafeez, S, Hansel, De, Hartmann, A, Hayne, D, Henry, Am, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, Ba, Jones, R, Kamat, Am, Khoo, V, Kiltie, Ae, Krege, S, Ladoire, S, Lara, Pc, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, Mc, Moschini, M, Mostafid, H, Muller, Ac, Muller, Cr, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, Jr, Oldenburg, J, Osanto, S, Oyen, Wjg, Pacheco-Figueiredo, L, Pappot, H, Patel, Mi, Pieters, Br, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, Je, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, Rj, Smits, A, Stenzl, A, Thalmann, Gn, Tombal, B, Turkbey, B, Lauridsen, Sv, Valdagni, R, Van der Heijden, Ag, Van Poppel, H, Vartolomei, Md, Veskimae, E, Vilaseca, A, Rivera, Fav, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Horwich, A

Subjects
Treatment, Consensus, Follow-up, education, Bladder cancer, Diagnosis, Consensu, Delphi, Diagnosi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.Setting: Online Delphi survey and consensus conference.Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as >= 70% agreement and

Published
2020

20. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study

Author

Nicosia, L., primary, Franceschini, D., additional, Perrone-Congedi, F., additional, Casamassima, F., additional, Gerardi, M.A., additional, Rigo, M., additional, Mazzola, R., additional, Perna, M., additional, Scotti, V., additional, Fodor, A., additional, Iurato, A., additional, Pasqualetti, F., additional, Gadducci, G., additional, Chiesa, S., additional, Niespolo, R.M., additional, Bruni, A., additional, Alicino, G., additional, Frassinelli, L., additional, Borghetti, P., additional, Di Marzo, A., additional, Ravasio, A., additional, De Bari, B., additional, Sepulcri, M., additional, Aiello, D., additional, Mortellaro, G., additional, Sangalli, C., additional, Franceschini, M., additional, Montesi, G., additional, Aquilanti, F.M., additional, Lunardi, G., additional, Valdagni, R., additional, Fazio, I., additional, Scarzello, Giovanni, additional, Corti, L., additional, Vavassori, V., additional, Maranzano, E., additional, Magrini, S.M., additional, Arcangeli, S., additional, Gambacorta, Maria Antonietta, additional, Valentini, V., additional, Paiar, F., additional, Ramella, S., additional, Di Muzio, N.G., additional, Livi, L., additional, Jereczek-Fossa, B.A., additional, Osti, M.F., additional, Scorsetti, M., additional, and Alongi, F., additional

Published
2022
Full Text
View/download PDF

23. A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer: The LaIT-SABR Study

Author

Nicosia, L., primary, Franceschini, D., additional, Perrone, F., additional, Casamassima, F., additional, Gerardi, M.A., additional, Perna, M., additional, Scotti, V., additional, Fodor, A., additional, Mazzola, R., additional, Rigo, M., additional, Iurato, A., additional, Pasqualetti, F., additional, Chiesa, S., additional, Niespolo, R.M., additional, Bruni, A., additional, Frassinelli, L., additional, Borghetti, P., additional, Marzo, A. Di, additional, Ravasio, A., additional, De Bari, B., additional, Sepulcri, M., additional, Aiello, D., additional, Mortellaro, G., additional, Sangalli, C., additional, Franceschini, M., additional, Montesi, G., additional, Aquilanti, F.M., additional, Valdagni, R., additional, Fazio, I., additional, Corti, L., additional, Vavassori, L., additional, Maranzano, E., additional, Magrini, S., additional, Lohr, F., additional, Arcangeli, S., additional, Valentini, V., additional, Paiar, F., additional, Ramella, S., additional, Di Muzio, N.G., additional, Livi, L., additional, Jereczek-Fossa, B.A., additional, Osti, M.F., additional, Scorsetti, M., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

26. PH-0112 Multicenter large retrospectIve database on SBRT for colorectal lung metastases: the LaIT-SABR study

Author

Nicosia, L., primary, Franceschini, D., additional, Perrone Congedi, F., additional, Casamassima, F., additional, Gerardi, M.A., additional, Perna, M., additional, Scotti, V., additional, Fodor, A., additional, Mazzola, R., additional, Rigo, M., additional, Iurato, A., additional, Pasqualetti, F., additional, Gadducci, G., additional, Chiesa, S., additional, Niespolo, R.M., additional, Bruni, A., additional, Frassinelli, L., additional, Borghetti, P., additional, Di Marzo, A., additional, Ravasio, A., additional, De Bari, B., additional, Sepulcri, M., additional, Aiello, D., additional, Mortellaro, G., additional, Sangalli, C., additional, Franceschini, M., additional, Montesi, G., additional, Aquilanti, F.M., additional, Valdagni, R., additional, Fazio, I., additional, Corti, L., additional, Vavassori, L., additional, Maranzano, E., additional, Magrini, S.M., additional, Lohr, F., additional, Arcangeli, S., additional, Valentini, V., additional, Paiar, F., additional, Ramella, S., additional, Di Muzio, N.G., additional, Livi, L., additional, Jereczek-Fossa, B.A., additional, Osti, M.F., additional, Scorsetti, M., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

32. Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series

Author

A. Saidi, Mahmut Ozsahin, Jean Bourhis, D. Hahnloser, M. Montemurro, Maira Biggiogero, Alessandra Franzetti-Pellanda, Michele Zeverino, and De Bari B

Subjects
Adult, Male, 0301 basic medicine, Antimetabolites, Antineoplastic, Cancer Research, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Original Article – Clinical Oncology, Image-guided radiotherapy, Tomotherapy, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic/therapeutic use, Capecitabine/therapeutic use, Chemoradiotherapy, Adjuvant, Female, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Radiotherapy, Image-Guided, Rectal Neoplasms/diagnostic imaging, Rectal Neoplasms/drug therapy, Rectal Neoplasms/radiotherapy, Rectal Neoplasms/therapy, Tomography, X-Ray Computed, Whole Body Imaging, Helical tomotherapy, Neoadjuvant chemoradiotherapy, Rectal cancer, Toxicity, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, medicine, Chemotherapy, Rectal Neoplasms, business.industry, Correction, General Medicine, medicine.disease, Confidence interval, Radiation therapy, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Radiology, business, medicine.drug
Abstract

Purpose Helical tomotherapy (HT) has been recently introduced in the neoadjuvant treatment of locally advanced rectal cancer. Aim of this study is to report the toxicity and local control rates of a large series of locally advanced rectal cancer patients treated with neoadjuvant chemotherapy and HT under daily image guidance followed by surgery. Methods Data from 117 locally advanced rectal cancer patients treated at two Swiss Radiotherapy departments were collected and analyzed. Radiotherapy consisted of 45 Gy (1.8 Gy/fraction, 5 fractions/week delivered in 5 weeks) to the regional pelvic lymph nodes. Seventy patients also received a simultaneous integrated boost (SIB) up to 50 Gy to the tumor and involved nodes (2 Gy/fraction, 5 fractions/week delivered in 5 weeks). Chemotherapy consisted of capecitabine 825 mg/m2, twice daily, during the irradiation days. After a median interval of 59 days [95% confidence interval (CI) 53–65 days), all patients underwent surgery. Results Median follow-up was 45 months (range 4–90 months). The overall rate of acute grade 2–4 toxicity was 18.8% (n = 22). Four patients (3.4%) presented a grade 3 dermatitis (n = 1) or diarrhea (n = 3), and 1 (0.8%) demonstrated grade 4 rectal toxicity. No patients presented with grade ≥ 3 hematologic toxicity. Six patients (5.1%) had late grade 3 gastrointestinal toxicity. The 4-year local control rate was 88.4% (95% CI 87.5–88.5%). Conclusions Neoadjuvant chemoradiotherapy delivered with HT under daily image guidance is well tolerated and shows a high 4-year local control rates.

Published
2019

38. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

Author

Witjes, J.A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. De Blok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Mir, M.C. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Lauridsen, S.V. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Rivera, F.A.V. Wiegel, T. Wiklund, P. Willemse, P.-P.M. Williams, A. Zigeuner, R. Horwich, A.

Abstract

The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands © 2019 European Society of Medical Oncology and European Association of Urology

Published
2020

39. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Subjects
Consensus, Follow-up, education, Bladder cancer, Diagnosis, Treatment, Delphi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

40. A Multicenter Large Retrospective Database On The Personalization Of Stereotactic Ablative Radiotherapy For Lung Metastases From Colon-rectal Cancer: Early Results From The LaIT-SABR Study

Author

Nicosia, L., primary, Rigo, M., additional, Franceschini, D., additional, Scorsetti, M., additional, Perrone, F., additional, Osti, M.F., additional, Ravasio, A., additional, Vavassori, V., additional, Borghetti, P., additional, Magrini, S., additional, Bruni, A., additional, Frassinelli, L., additional, Lohr, F., additional, Di Marzo, A., additional, Maranzano, E., additional, Slimani, S., additional, De Bari, B., additional, Mazzola, R., additional, and Alongi, F., additional

Published
2020
Full Text
View/download PDF

41. OC-0694: An ESTRO-ACROP Delphi consensus on salvage SBRT for intraprostatic relapse after PCa radiotherapy

Author

Jereczek-Fossa, B.A., primary, Marvaso, G., additional, Pepa, M., additional, Gugliandolo, S.G., additional, Zerini, D., additional, Gandini, S., additional, Vavassori, A., additional, De Bari, B., additional, Alongi, F., additional, Fonteyne, V., additional, Pieters, B., additional, Hoskin, P., additional, Tree, A., additional, Bossi, A., additional, Cornford, P., additional, Toledano, A., additional, Hannoun-Levi, J., additional, Miralbell, R., additional, Fuller, D., additional, Scorsetti, M., additional, Arcangeli, S., additional, Livi, L., additional, Janoray, G., additional, Pasquier, D., additional, and Ost, P., additional

Published
2020
Full Text
View/download PDF

42. PO-0956: Neuroendocrine Tumors of the Breast: an international series of the Rare Cancer Network

Author

Grellier-Adedjouma, N., primary, Paix, A., additional, Franco, P., additional, Kirova, Y.M., additional, De Bari, B., additional, Pasquier, D., additional, Meijer, H., additional, Oksüz, D.C., additional, Peignaux-Casasnovas, K., additional, Huguet, F., additional, De Caluwé, A., additional, Khanfir, K., additional, Vargas, A., additional, Thariat, J., additional, Vargo, J.A., additional, Ozsahin, E.M., additional, and Belkacemi, Y., additional

Published
2020
Full Text
View/download PDF

43. 492P A multicenter LArge retrospectIve daTabase on the personalization of Stereotactic ABlative Radiotherapy for lung metastases from colorectal cancer: Early results from the LaIT-SABR study

Author

Nicosia, L., primary, Rigo, M., additional, Franceschini, D., additional, Scorsetti, M., additional, Congedi, F. Perrone, additional, Osti, M.F., additional, Ravasio, A., additional, Vavassori, V., additional, Borghetti, P., additional, Magrini, S.M., additional, Bruni, A., additional, Frassinelli, L., additional, Lohr, F., additional, Di Marzo, A., additional, Maranzano, E., additional, De Bari, B., additional, Mazzola, R., additional, and Alongi, F., additional

Published
2020
Full Text
View/download PDF

44. Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients

Author

Kim, S., primary, Meurisse, A., additional, Stouvenot, M., additional, Jary, M., additional, Hon, T Nguyen Tan, additional, Francois, E., additional, Buecher, B., additional, Andre, T., additional, Samalin, E., additional, Boulbair, F., additional, De Bari, B., additional, Almotlak, H., additional, Klajer, E., additional, Calcagno, F., additional, Chatillon, E., additional, Spehner, L., additional, Jacquin, M., additional, Vendrely, V., additional, Vernerey, D., additional, and Borg, C., additional

Published
2019
Full Text
View/download PDF

45. Development and validation of a PET-based nomogram predictive for survival of oropharyngeal cancer patients

Author

Castelli Joel, Depeursinge Adrien, Ndoh Vanessa, Prior John O., Ozsahin Esat, Devillers Anne, Bouchaab Hanan, Chajon Enrique, De Crevoisier R., Scher Nathaniel, Jegoux F., Laguerre B., De Bari B., and Bourhis J.

Abstract

Purpose: In the context of locally advanced oropharyngeal cancer (LAOC) treated with definitive radiotherapy (RT) (combined with chemotherapy or cetuximab) the aims of this study were: (1) to identify PET FDG parameters correlated with overall survival (OS) from a first cohort of patients; then (2) to compute a prognostic score; and (3) finally to validate this scoring system in a second independent cohort of patients. Materials and methods: A total of 76 consecutive patients (training cohort from Rennes) treated with chemoradiotherapy or RT with cetuximab for LAOC were used to build a predictive model of locoregional control (LRC) and OS based on PET FDG parameters. After internal calibration and validation of this model a nomogram and a scoring system were developed and tested in a validation cohort of 46 consecutive patients treated with definitive RT for LAOC in Lausanne. Results: In multivariate analysis the metabolic tumour volume (MTV) of the primary tumour and the lymph nodes were independent predictive factors for LRC and OS. Internal calibration showed a very good adjustment between the predicted OS and the observed OS at 24 months. Using the predictive score two risk groups were identified (median OS 42 versus 14 months p < 0.001) and confirmed in the validation cohort from Lausanne (median OS not reached versus 26 months p = 0.008). Conclusions: This is the first report of a PET based nomogram in oropharyngeal cancer. Interestingly it appeared stronger than the classical prognostic factors and was validated in independent cohorts markedly diverging in many aspects which suggest that the observed signal was robust.

Published
2017

46. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. DeBlok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Carmen Mir, M. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Vahr Lauridsen, S. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Vives Rivera, F.A. Wiegel, T. Wiklund, P. Williams, A. Zigeuner, R. Witjes, J.A.

Subjects
education
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © 2019 European Society for Medical Oncology

Published
2019

47. Understanding the anti-tumor T cell responses modulation mediated by chemoradiation to improve immunotherapy efficacy

Author

Lauret, E., primary, Bonin, C., additional, Rangan, L., additional, Boullerot, L., additional, Boustani, J., additional, Fagnoni-Legat, C., additional, Perrin, S., additional, Mirjolet, C., additional, Dosset, M., additional, Boidot, R., additional, Servagi, S., additional, De Bari, B., additional, and Adotevi, O., additional

Published
2018
Full Text
View/download PDF

48. Clinical Outcomes of Rectal Squamous Cell Carcinomas Treated with Chemoradiotherapy with or Without Surgery: A Rare Cancer Network Study.

Author

De Bari, B., primary, Aloi, D., additional, Lemanski, C., additional, Hallemeier, C.L., additional, Touboul, E., additional, Qi, S., additional, Christie, D., additional, Vees, H., additional, Shulman, K., additional, Atasoy, B.M., additional, Sefik, I., additional, Micke, O., additional, Servagi Vernat, S., additional, and Khanfir, K., additional

Published
2018
Full Text
View/download PDF

49. Radiation Therapy in Extracranial Chondrosarcomas: A Multicenter French Sarcoma Group and Rare Cancer Network Study

Author

Terlizzi, M., primary, Rapeaud, E., additional, Le Pechoux, C., additional, Salas, S., additional, Lerouge, D., additional, Sunyach, M.P., additional, Vogin, G., additional, Sole, C.V., additional, Zilli, T., additional, Myroslav, L., additional, Mampuya, A., additional, Calvo, F.A., additional, Attal, J., additional, De Bari, B., additional, Ozsahin, M., additional, Sargos, P., additional, and Thariat, J.O., additional

Published
2018
Full Text
View/download PDF

50. Adaptive radiotherapy for head and neck cancer

Author

Castelli, J., primary, Simon, A., additional, Lafond, C., additional, Perichon, N., additional, Rigaud, B., additional, Chajon, E., additional, De Bari, B., additional, Ozsahin, M., additional, Bourhis, J., additional, and de Crevoisier, R., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results